At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CYPH Cypherpunk Technologies Inc.
Market Closed 09-25 16:00:00 EDT
4.12
+0.04
+0.98%
盘后4.14
+0.02+0.60%
19:59 EDT
High4.19Low3.82Vol19.97M
Open3.96D1 Closing4.08Amplitude9.07%
Mkt Cap443.99MTradable Cap309.26MTotal Shares107.76M
T/O80.14MT/O Rate26.60%Tradable Shares75.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cypherpunk Technologies Appoints Nakamoto COO Amanda Fabiano to Board
Reuters  ·  09-22
Cypherpunk Technologies Appoints Nakamoto COO Amanda Fabiano to Board
Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors
THOMSON REUTERS  ·  09-22
Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors
Cypherpunk Technologies is Maintained at Overweight by Cantor Fitzgerald
Dow Jones  ·  09-10
Cypherpunk Technologies is Maintained at Overweight by Cantor Fitzgerald
Cypherpunk Technologies price target raised to $4.90 from $1.60 at Cantor Fitzgerald
TIPRANKS  ·  09-10
Cypherpunk Technologies price target raised to $4.90 from $1.60 at Cantor Fitzgerald
Cypherpunk Regains NASDAQ Compliance with $1 Minimum Bid Price Rule
Reuters  ·  09-03
Cypherpunk Regains NASDAQ Compliance with $1 Minimum Bid Price Rule
Cypherpunk Director Thomas John Dietz Sells 20,000 Common Shares for $34,400
Reuters  ·  08-28
Cypherpunk Director Thomas John Dietz Sells 20,000 Common Shares for $34,400
Cypherpunk Technologies Price Target Maintained with a $1.60/Share by Cantor Fitzgerald
Dow Jones  ·  08-27
Cypherpunk Technologies Price Target Maintained with a $1.60/Share by Cantor Fitzgerald
Cypherpunk Technologies Files Form 3 for Head of Mining Kevin Zhang Stake
Reuters  ·  08-25
Cypherpunk Technologies Files Form 3 for Head of Mining Kevin Zhang Stake
Analysts Are Bullish on Top Financial Stocks: Ares Capital (ARCC), Cypherpunk Technologies (CYPH)
TIPRANKS  ·  08-24
Analysts Are Bullish on Top Financial Stocks: Ares Capital (ARCC), Cypherpunk Technologies (CYPH)
Top Premarket Gainers
MT Newswires Live  ·  08-24
Top Premarket Gainers
Cypherpunk Technologies is Maintained at Overweight by Cantor Fitzgerald
Dow Jones  ·  08-19
Cypherpunk Technologies is Maintained at Overweight by Cantor Fitzgerald
Cypherpunk Technologies: Launches Cypherpunk Mining Through a $33.33 Million Equity-Based Transaction with Winklevoss Capital
THOMSON REUTERS  ·  08-18
Cypherpunk Technologies: Launches Cypherpunk Mining Through a $33.33 Million Equity-Based Transaction with Winklevoss Capital
Cypherpunk Names Kevin Zhang Head of Mining
Reuters  ·  08-18
Cypherpunk Names Kevin Zhang Head of Mining
Cypherpunk Technologies Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Cypherpunk Technologies Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Cypherpunk Technologies Q2 Adj. EPS $(0.03), Inline
Benzinga Earnings  ·  08-12
Cypherpunk Technologies Q2 Adj. EPS $(0.03), Inline
Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains
Reuters  ·  08-12
Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains
Cypherpunk Q2 FY26 Net Income Swings to $39.4 Million; Operating Loss Narrows to $4.69 Million
Reuters  ·  08-12
Cypherpunk Q2 FY26 Net Income Swings to $39.4 Million; Operating Loss Narrows to $4.69 Million
Cypherpunk Technologies Inc Q2 Net Income USD 39.4 Million
THOMSON REUTERS  ·  08-12
Cypherpunk Technologies Inc Q2 Net Income USD 39.4 Million
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
THOMSON REUTERS  ·  08-12
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
Cypherpunk Unit Leap Therapeutics Reports DeFianCe Phase 2 Sirexatamab Results Published in Clinical Cancer Research
Reuters  ·  08-12
Cypherpunk Unit Leap Therapeutics Reports DeFianCe Phase 2 Sirexatamab Results Published in Clinical Cancer Research

Introduction

Company Name.
Cypherpunk Technologies Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Issue price:
--